Ghazanfar Abdullah
Bronx, NYNPI 1639108137
Payments from drug & device makers
Across 832 payments — averaging $40.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$12K
- Gilead$9K
- Johnson & Johnson$2K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Napo Pharmaceuticals Inc$1K
- plus $5K from 19 others
What the payments were for
- Consulting fees$7,74023%
- Speaking & faculty fees$1,2504%
- Travel & lodging$3,17910%
- Food & beverage$20,88062%
- Education$3831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 197 | $11,935 |
| Gilead | 209 | $9,026 |
| Johnson & Johnson(2 entities) | 99 | $2,457 |
| AbbVie | 92 | $1,992 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 88 | $1,878 |
| Napo Pharmaceuticals Inc | 2 | $1,376 |
| Janssen Products, LP | 12 | $1,330 |
| Merck | 27 | $679 |
| Paratek Pharmaceuticals, Inc. | 24 | $629 |
| Forte Bio-pharma LLC | 22 | $486 |
| Orexo US, Inc. | 18 | $362 |
| Lilly USA, LLC | 4 | $246 |
| Mannkind Corporation | 2 | $232 |
| Madrigal Pharmaceuticals | 5 | $142 |
| Neurocrine Biosciences, Inc. | 5 | $103 |
| GSK | 4 | $82 |
| Pfizer | 3 | $82 |
| Boehringer Ingelheim | 3 | $77 |
| Nestle Healthcare Nutrition Inc. | 3 | $72 |
| Alkermes, Inc. | 3 | $65 |
| Lundbeck LLC | 3 | $43 |
| Althera Pharmaceuticals LLC | 2 | $42 |
| IBSA Pharma Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $38 |
| Indivior Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 231 | $881,544 |
| DovatoDolutegravir Sodium/Lamivudine | 228 | $626,454 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 112 | $390,422 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 72 | $293,849 |
| RelistorMethylnaltrexone Bromide | 87 | $192,430 |
| DescovyEmtricitabine/Tenofov Alafenam | 71 | $144,273 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 19 | $69,913 |
| JardianceEmpagliflozin | 111 | $64,883 |
| TivicayDolutegravir Sodium | 31 | $60,337 |
| Clemastine Fumarate | 12 | $57,681 |
| Megestrol Acetate | 202 | $49,957 |
| EdurantRilpivirine Hcl | 27 | $39,690 |
| MounjaroTirzepatide | 27 | $27,658 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 59 | $27,066 |
| Diclofenac Sodium | 69 | $26,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $9,026 | $1,095,730321 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $11,935 | $1,077,212371 claims |
| Janssen Products, LPSymtuza | $1,330 | $293,84972 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,878 | $192,43087 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Glyxambi, Spiriva Respimat | $77 | $156,715295 claims |
| PfizerSelzentry, Eliquis | $82 | $35,43536 claims |
| Lilly USA, LLCMounjaro | $246 | $27,65827 claims |
| GSKArnuity Ellipta, Incruse Ellipta | $82 | $19,66076 claims |
| Indivior Inc.Suboxone | $20 | $17,80223 claims |
| Johnson & JohnsonInvokana, Xarelto | $2,457 | $13,18823 claims |
| AbbVieRestasis | $1,992 | $10,27117 claims |
| MerckJanuvia | $679 | $7,90515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.